- Home
- CRIS vs CGTX Comparison
CRIS vs CGTX Comparison
Compare CRIS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | CGTX |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 94.5M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRIS | CGTX |
|---|---|---|
| Price | $0.56 | $0.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.67 | $3.33 |
| AVG Volume (30 Days) | 231.2K | ★ 984.8K |
| Earning Date | 03-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $32.24 | N/A |
| Revenue Next Year | $66.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.52 | $0.22 |
| 52 Week High | $3.13 | $3.83 |
Technical Indicators
Market Signals| Indicator | CRIS | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.10 | 23.20 |
| Support Level | N/A | $0.56 |
| Resistance Level | $1.04 | $1.19 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 5.16 | 0.00 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.